XML 37 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements
12 Months Ended
Dec. 28, 2018
Fair Value Disclosures [Abstract]  
Fair Value Measurements
FAIR VALUE MEASUREMENTS
The classification of our financial assets within the fair value hierarchy that were measured and recorded at fair value on a recurring basis was as follows (in thousands):
 
December 31, 2018
 
Level 1
 
Level 2
 
Total
Money market funds
$
47,744

 
$

 
$
47,744

Commercial paper

 
381,133

 
381,133

Corporate bonds

 
344,064

 
344,064

U.S. Treasury and government sponsored enterprises

 
55,201

 
55,201

Total investments available-for-sale
47,744

 
780,398

 
828,142

Certificates of deposit

 
16,596

 
16,596

Total financial assets carried at fair value
$
47,744

 
$
796,994

 
$
844,738

 
December 31, 2017
 
Level 1
 
Level 2
 
Total
Money market funds
$
45,478

 
$

 
$
45,478

Commercial paper

 
199,647

 
199,647

Corporate bonds

 
179,022

 
179,022

U.S. Treasury and government sponsored enterprises

 
16,263

 
16,263

Total investments available-for-sale
45,478

 
394,932

 
440,410

Certificates of deposit

 
13,498

 
13,498

Total financial assets carried at fair value
$
45,478

 
$
408,430

 
$
453,908


We did not have any financial liabilities measured and recorded at fair value on a recurring basis as of December 31, 2018 or December 31, 2017. We did not have any financial assets or liabilities classified as Level 3 in the fair value hierarchy as of December 31, 2018 or December 31, 2017. There were no transfers of financial assets or liabilities between Levels 1, 2 and 3 during the years ended December 31, 2018 or 2017.
When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.
See “Note 11. Commitments” regarding the determination of the amount of our operating lease liabilities as of December 31, 2018. Our remaining financial assets and liabilities include cash and restricted cash, Trade receivables, net, Other receivables, Accounts payable, Accrued compensation and benefits, Accrued clinical trial liabilities, Accrued collaboration liabilities, Rebates and fees due to customers and other current and long-term liabilities. Those financial assets and liabilities are carried at cost which approximates their fair values.